KLBF - Expanding its export market

KLBF - Expanding its export market Kalbe Farma (KLBF) through its subsidiary, Kalbe Genexine Biologics (KGBio), collaborates with Shanghai Henlius Biotech to market Hansizhuang to North African and 12 Middle Eastern countries; Arabia, the United Arab Emirates, Egypt, Qatar, Jordan, Morocco, Algeria, Libya, Iraq and surrounding areas. Note that, Hansizhuang is a new anti-PD-1 (mAB) monoclonal antibody product combined with chemotherapy or a first line medication drugs for an Extensive Stage - Small Cell Lung Carcinoma/cancer (ES-SCLC) illness. This product is already certified halal which could attract ASEAN, Middle East and Africa countries. Previously, KLBF has cooperated in marketing with 10 ASEAN countries. Moreover, KLBF has invested in a production facility in Cikarang, West Java, which the investment cost for 1 clinical trial of this product until phase 3 is around IDR100-200 bn. In 1H23, KLBF's exports reached IDR921.53 bn (+42.65% yoy); IDR406.94 bn from prescription drug segment, IDR336.48 bn from consumer health, IDR177 bn from nutritional segment and IDR1 bn from distribution and logistics segment. (Source : Kontan)